TY - JOUR T1 - Global immune fingerprinting in glioblastoma reveals immune-suppression signatures associated with prognosis JF - bioRxiv DO - 10.1101/309807 SP - 309807 AU - Tyler J. Alban AU - Alvaro G. Alvarado AU - Mia D. Sorensen AU - Defne Bayik AU - Josephine Volovetz AU - Emily Serbinowski AU - Erin E. Mulkearns-Hubert AU - Maksim Sinyuk AU - James S. Hale AU - Giovana R. Onzi AU - Mary McGraw AU - Pengjing Huang AU - Matthew M. Grabowski AU - Connor A. Wathen AU - Tomas Radivoyevitch AU - Harley I. Kornblum AU - Bjarne W. Kristensen AU - Michael A. Vogelbaum AU - Justin D. Lathia Y1 - 2018/01/01 UR - http://biorxiv.org/content/early/2018/05/11/309807.abstract N2 - Glioblastoma (GBM) remains uniformly lethal, and, despite a large accumulation of immune cells in the microenvironment, there is limited anti-tumor immune response, even with newly developed immune checkpoint therapies. To overcome these challenges and enhance the efficacy of immunotherapies, a comprehensive understanding of the immune system in GBM and changes during disease progression is required. Here, we integrated multi-parameter flow cytometry and mass cytometry time of flight (CyTOF) analysis of patient blood to determine changes in the immune system among tumor types and over disease progression. Utilizing multi-parameter flow cytometry analysis in a cohort of over 250 patients with brain tumors ranging from benign to malignant primary and metastatic, we found that GBM patients had a significant elevation in myeloid-derived suppressor cells (MDSCs) in blood, but not immunosuppressive T regulatory cells. We validated these findings in GBM patient tissue and found that increased numbers of MDSCs in recurrent GBM portended poor prognosis. CyTOF analysis of peripheral blood from a cohort of newly diagnosed GBM patients revealed that reduction in MDSC frequency over time is accompanied by a concomitant increase in dendritic cells and natural killer cells. This reduced MDSC profile was present in GBM patients with extended survival and was similar to that of low-grade glioma (LGG) patients. Our findings provide a rationale for developing strategies to target MDSCs, which are elevated in GBM patients and predict poor prognosis, either by directly targeting or by shifting the immune profile to induce differentiation toward the immune profile of LGGs. ER -